Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Breast Cancer

Neoadjuvant docetaxel combined with adjuvant doxorubicin and cyclophosphamide

Researchers in the United States conducted a study "to evaluate clinical and pathologic response to neoadjuvant docetaxel therapy in patients with stage III breast cancer. Forty-five patients were planned to receive four cycles of docetaxel 100 mg/m² every 3 weeks, followed by surgery, four cycles of doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC) every 3 weeks, radiation therapy (RT), and tamoxifen when indicated."

"After four cycles of neoadjuvant docetaxel, the clinical response rate within the...

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications